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CeBACKGROUND Pulmonary hypertension and associated right ventricular (RV) dysfunction are important determinants
of morbidity and mortality, which are optimally characterized by invasive hemodynamic measurements.
OBJECTIVES This study sought to determine whether metabolite proﬁling could identify plasma signatures of right
ventricular-pulmonary vascular (RV-PV) dysfunction.
METHODS We measured plasma concentrations of 105 metabolites using targeted mass spectrometry in 71 individuals
(discovery cohort) who underwent comprehensive physiological assessment with right-sided heart catheterization and
radionuclide ventriculography at rest and during exercise. Our ﬁndings were validated in a second cohort undergoing
invasive hemodynamic evaluations (n¼ 71), as well as in an independent cohort with or without known pulmonary arterial
(PA) hypertension (n ¼ 30).
RESULTS In the discovery cohort, 21 metabolites were associated with 2 or more hemodynamic indicators of RV-PV
function (i.e., resting right atrial pressure, mean PA pressure, pulmonary vascular resistance [PVR], and PVR and PA
pressure-ﬂow response [DPQ] during exercise). We identiﬁed novel associations of RV-PV dysfunction with circulating
indoleamine 2,3-dioxygenase (IDO)–dependent tryptophan metabolites (TMs), tricarboxylic acid intermediates, and
purine metabolites and conﬁrmed previously described associations with arginine–nitric oxide metabolic pathway
constituents. IDO-TM levels were inversely related to RV ejection fraction and were particularly well correlated with
exercise PVR and DPQ. Multisite sampling demonstrated transpulmonary release of IDO-TMs. IDO-TMs also identiﬁed
RV-PV dysfunction in a validation cohort with known risk factors for pulmonary hypertension and in patients with
established PA hypertension.
CONCLUSIONS Metabolic proﬁling identiﬁed reproducible signatures of RV-PV dysfunction, highlighting both new
biomarkers and pathways for further functional characterization. (J Am Coll Cardiol 2016;67:174–89)
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AB BR E V I A T I O N S
AND ACRONYM S
BMI = body mass index
CPET = cardiopulmonary
exercise test
DPQ = change in mean
pulmonary arterial pressure
relative to change in cardiac
output
IDO = indoleamine
2,3-dioxygenase
IDO-TM = indoleamine
2,3-dioxygenase–dependent
tryptophan metabolite
IL = interleukin
LC-MS = liquid
chromatography mass
spectrometry
LV = left ventricular
LVEF = left ventricular
ejection fraction
NO = nitric oxide
NT-proBNP = N-terminal
pro–B-type natriuretic peptide
PAH = pulmonary arterial
hypertension
PAP = pulmonary arterial
pressure
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175T here is an unmet clinical need to developnew circulating biomarkers of pulmonaryhypertension (PH). Novel biomarkers of
right ventricular (RV)–pulmonary vascular (PV)
dysfunction might aid in earlier PH detection and
inform selection of patients for PH-speciﬁc therapies,
while reducing reliance on subjective measures (e.g.,
functional class) and invasive hemodynamic assess-
ment. The proﬁling of metabolites, including lipids,
sugars, nucleotides, amino acids, and amines, is
particularly relevant to the understanding of RV-PV
dysfunction. Studies in both experimental models
and patients have suggested a maladaptive imbalance
between pulmonary vasodilators and vasoconstric-
tors in RV-PV dysfunction. Several small-molecule
mediators of PV tone have been identiﬁed, including
the nitric oxide (NO) second messenger cyclic guano-
sine monophosphate, prostaglandins, and other
biogenic amines (1–3). PV remodeling and right ven-
tricular (RV) hypertrophy have been associated with
a potential switch from fatty acid oxidation to glycol-
ysis (4,5), which provides further motivation to apply
a more global metabolite proﬁling approach to PH. Ul-
timately, metabolite proﬁling might highlight mea-
sures to redress metabolic derangements in RV-PV
dysfunction (6,7).SEE PAGE 190 PAWP = pulmonary arterial
wedge pressure
PH = pulmonary hypertension
PV = pulmonary vascular
PVR = pulmonary vascular
resistance
RAP = right atrial pressure
RNA = ribonucleic acid
RV = right ventricular
RVEF = right ventricular
ejection fraction
RV-PV = right ventricular-
pulmonary vascular
TCA = tricarboxylic acid
TH = tryptophan hydroxylase
TM = tryptophan metaboliteIn this study, we hypothesized that simultaneous
invasive hemodynamic measurements during right-
sided heart catheterization and blood sampling in
dyspneic subjects would permit derivation of meta-
bolic signatures of RV-PV dysfunction. We recruited
subjects with dyspnea and a wide range of right-sided
heart catheterization hemodynamic proﬁles, as well as
predeﬁned groups of people with and without known
World Health Organization Group 1 pulmonary arterial
hypertension (PAH), to identify metabolite proﬁles of
RV-PV dysfunction. We performed blood sampling
in multiple anatomic sites to localize the source of
metabolic signatures. To optimize the precision
of our phenotyping of RV-PV dysfunction, we also
measured the degree of impairment in exercise ca-
pacity (peak oxygen uptake [VO2]) and performed
minute-by-minute hemodynamic measurements
across varying RV loading conditions during exercise
to probe the capacity of the RV-PV unit toHL131029, and NIH R01 HL119154 (Bethesda, Maryland), American Heart A
Texas), and the Hassenfeld Clinical Scholar Award (Boston, Massachusetts). D
Gilead. Dr. Gerszten was supported by an AHA Established Investigator Award
they have no relationships relevant to the contents of this paper to disclose
Manuscript received August 12, 2015; revised manuscript received October 6accommodate increased blood ﬂow (8).
Furthermore, we used a well-described ani-
mal model to evaluate the expression of key
enzymes and metabolites in an emerging
pathway associated with PH in our human
studies.
METHODS
We enrolled 2 consecutive cohorts of patients
who underwent cardiopulmonary exercise
testing (CPET) with invasive hemodynamic
monitoring at Massachusetts General Hospital
to evaluate dyspnea on exertion. Patients
provided informed consent to participate in
this study. Exclusion criteria consisted of the
following: 1) left ventricular (LV) systolic
dysfunction (left ventricular ejection fraction
[LVEF] <0.45) or severe valvular heart dis-
ease; 2) chronic kidney disease (worse than
stage 3); 3) parenchymal lung disease with a
pulmonary mechanical limitation to exercise
as deﬁned by minute ventilation (VE)/(forced
expiratory volume in 1 s [FEV1]  35) >0.7
at the ventilatory anaerobic threshold (9); or
4) incomplete pulmonary arterial catheter
pressure measurements.
A third cohort was prospectively recruited
from patients referred to the Vanderbilt Pul-
monary Hypertension Clinic who were diag-
nosed with right-sided heart catheterization–
proven PAH attributable to idiopathic, heri-
table, drug- or toxin-associated, or connec-
tive tissue disease–associated PAH and who
provided consent for having their blood
drawn. The control subjects were recruited
prospectively from an e-mail distribution to
all Vanderbilt employees seeking healthy in-
dividuals of similar age, sex, and body mass
index (BMI) to enroll as control subjects in
their PAH clinic blood sampling study. The
human studies were approved by the Partners
Healthcare System and Vanderbilt University
Institutional Review Boards.
Subjects in the ﬁrst 2 cohorts were mandated to
be fasting for at least 8 h before CPET and blood
draws for metabolite measurements. Invasive CPETssociation (AHA) grant 15GPSGC24800006 (Dallas,
r. Pugh has served as an advisory board member for
(Dallas, Texas). All other authors have reported that
.
, 2015, accepted October 13, 2015.
TABLE 1 Clinical Characteristics
Derivation Cohort (n ¼ 71) Validation Cohort (n ¼ 71)
Age, yrs 62  13 60  14
Female 62 53
Ethnicity (C, AA, H) 96, 0, 4 96, 1, 3
BMI, kg/m2 29.2  5.9 28  4.2
Creatinine, g/dl 1.1  0.3 1.1  0.4
Hypertension 58 58
Diabetes mellitus 24 24
Dyslipidemia 49 45
Active smoking 3 10
Active cancer 0 0
Medications
Beta-blocker 37 31
ACEI/ARB 34 30
CCB 20 12
Diuretic agent 40 31
Statin 42 45
Insulin 10 10
NT-proBNP, pg/ml 820  1,266 662  1,170
RVEF
At rest 0.50  0.08 0.48  0.07
Exercise 0.50  0.09 0.48  0.07
LVEF
At rest 0.64  0.09 0.62  0.07
Exercise 0.65  0.08 0.64  0.07
Heart rate, beats/min
At rest 76  14 77  5
Exercise 128  24 132  29
Systolic BP, mm Hg
At rest 136  19 142  22
Exercise 182  32 180  38
Diastolic BP, mm Hg
At rest 79  12 75  13
Exercise 88  15 85  15
Workload, W 90  47 103  49
Peak VO2, ml/kg/min 15.4  5.8 17.3  6.0
RAP, mm Hg
At rest 7  3 5  3
Exercise 11  5 11  4
mPAP, mm Hg
At rest 21  9 23  8
Exercise 38  11 41  13
PAWP, mm Hg
At rest 13  5 11  5
Exercise 21  6 19  6
Continued on the next page
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176with ﬁrst-pass radionuclide ventriculography was
performed as described previously (7,10) (Online
Appendix, Online Figure 1). In the third PAH versus
control validation cohort, peripheral venous plasma
samples were obtained in the fasting state at 3 (me-
dian interquartile range: 0 to 6) days from the time of
right-sided heart catheterization documenting PAH.
Proﬁles of plasma metabolites were obtained by
use of a multiplexed liquid chromatography mass
spectrometry (LC-MS) system as described previously(11) (Online Appendix). Additionally, commercially
available enzyme-linked immunosorbent assays were
used to measure N-terminal pro–B-type natriuretic
peptide (NT-proBNP), cystatin C, and interleukin
(IL)-6 levels from separate aliquots of the same sam-
ples used for LC-MS analysis of metabolites.
ANIMAL MODEL OF PH. Male C57Bl/6 mice (8 to
10 weeks old) were obtained from the Jackson Labo-
ratory (Bar Harbor, Maine). Mice were housed in
specially designed cage racks and exposed to chronic
hypoxia (FIO2 0.10) or room air (control) for 3 weeks.
All animal studies were approved by the Institutional
Animal Care and Use Committee of the Massachusetts
General Hospital and conformed to the position of
the American Heart Association on animal use. After
mice were euthanized, blood was collected via LV
puncture, and a thoracotomy was performed for heart
and lung harvesting. RV hypertrophy was calculated
as the ratio of the RV wall weight to LV wall plus
septum weight (RV/[LV þ S]  Fulton ratio).
Blood samples from the mice were centrifuged at
8,000 revolutions/min for 5 min at 4C. Plasma was
immediately stored at 80C. Lung tissue was snap
frozen in liquid nitrogen immediately after harvest
and stored at 80C. For homogenization of the lung,
25 mg of tissue sample was mixed with 250 ml of
50:50 methanol:water solution. The tissue was ho-
mogenized for 4 min at 25 Hz in the Tissue Lyser II
(Qiagen, Hilden, Germany). Metabolite proﬁling was
performed on plasma and lung homogenate as
described previously for the human plasma samples.
Indoleamine 2,3-dioxygenase-dependent (IDO) ribo-
nucleic acid (RNA) content was measured by quanti-
tative real-time polymerase chain reaction (Online
Appendix).
STATISTICAL ANALYSES. All metabolite values and
NT-proBNP levels were log-transformed because of
non-normal distribution. Age- and sex-adjusted
Pearson correlation coefﬁcients were calculated
to determine correlations between metabolites
known to cluster within well-deﬁned groups (e.g.,
arginine-NO metabolites and tryptophan metabo-
lites). Linear regression analyses were performed to
examine the relation of each metabolite with hemo-
dynamic measurements that reﬂect RV-PV function:
right atrial pressure (RAP), pulmonary arterial pres-
sure (PAP), and pulmonary vascular resistance (PVR)
at rest, and PVR and change in mean PAP relative
to change in cardiac output (DPQ) during exercise.
Relationships between metabolites and pulmonary
arterial wedge pressure (PAWP) are included for the
sake of comparison of metabolite relationships to
left-sided heart ﬁlling pressures.
TABLE 1 Continued
Derivation Cohort (n ¼ 71) Validation Cohort (n ¼ 71)
Cardiac output, l/min
At rest 5.5  1.7 5.2  1.5
Exercise 11.6  3.5 11.2  3.6
PVR, WU
At rest 2.1  1.3 3.1  2.5
Exercise 1.7  1.2 2.2  1.4
DPQ, mm Hg/l/min 3.8  2.6 4.5  4.0
PH at rest 20 (28) 27 (38)
DPQ >3 mm Hg/l/min 35 (49) 42 (59)
Exercise PVR >1.5 WU 29 (41) 39 (55)
Values are mean  SD, %, or n (%).
AA ¼ African American; ACEI/ARB ¼ angiotensin-converting enzyme inhibitor/angiotensin
receptor blocker; BMI ¼ body mass index; BP ¼ blood pressure; C ¼ Caucasian; CCB ¼ calcium
channel blocker; H ¼ Hispanic; DPQ ¼ change in mean pulmonary arterial pressure; LVEF ¼ left
ventricular ejection fraction; mPAP ¼mean pulmonary arterial pressure; NT-proBNP ¼ N-terminal
pro-B-type natriuretic peptide; PAWP ¼ pulmonary arterial wedge pressure; PH ¼ pulmonary
hypertension; PVR ¼ pulmonary vascular resistance; RAP ¼ right atrial pressure; RVEF ¼ right
ventricular ejection fraction; VO2 ¼ oxygen uptake; WU ¼ Wood units.
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177Multimarker scores were created for metabolites
that cluster into known metabolic pathways if
multiple constituents demonstrated signiﬁcant asso-
ciations with hemodynamic indicators of RV-PV
function. Scores were derived by calculating the
sum of standardized biomarker values (z-scores)
weighted according to the value of their correspond-
ing b-coefﬁcients, as described previously (11). Mul-
timarker scores ﬁt to the derivation cohort that were
signiﬁcantly associated with RV-PV dysfunction were
then evaluated by linear regression in the second
validation cohort. Receiver operating coefﬁcient
analyses were performed to identify the ability of
metabolites to predict RV-PV dysfunction in the
validation cohort. The C-statistic was calculated by
assessing the proportion of cases (RV-PV dysfunction)
for which the biomarker value exceeded that in
controls (no RV-PV dysfunction).
To further validate novel circulating metabolites in
an independent cohort, we compared levels of IDO
tryptophan metabolites (IDO-TMs) in patients with
known PAH and control subjects. To have 80% power
to detect a 20% difference in 4 IDO-TMs with
p < 0.0125 (Bonferroni correction p ¼ 0.05 for 4 me-
tabolites) between groups, we performed metabolite
proﬁling in 11 patients with PAH and 19 control sub-
jects. Between-group comparisons were performed
for the PAH versus control cohort with Student t test
or Wilcoxon rank sum test, as appropriate. Additional
information regarding adjustment for multiple hy-
pothesis testing and regression models is available
in the Online Appendix. The STATA version 12.0
software package (StataCorp LP, College Station,
Texas) was used for statistical analysis.
RESULTS
CLINICAL CHARACTERISTICS. Study participants
undergoing CPET had an average age of 62 years in
both cohorts, with a slight female predominance
(Table 1). Average resting right-sided heart cathe-
terization measurements were in the high-normal
range. No patients demonstrated LV systolic dys-
function, as deﬁned by either an LVEF <0.45 at rest
or a fall in LVEF to <0.45 during exercise. Exercise
unmasked impaired RV-PV reserve function in both
the derivation and validation groups, as evidenced
by multipoint changes in DPQ and peak exercise PVR
(Table 1). In the setting of these hemodynamic pro-
ﬁles, average exercise capacity was reduced in both
the derivation and validation cohorts (peak VO2 ¼ 62
 13% predicted and 66  14% predicted (12),
respectively).ANALYTES ASSOCIATEDWITH RV-PV DYSFUNCTION. We
measured 5 hemodynamic indicators of RV-PV
dysfunction (resting RAP, PAP, PVR, exercise PVR,
and DPQ). We integrated the hemodynamic mea-
surements with mass spectrometry–based analyses
of metabolites (Figure 1), identifying 21 metabolites
that were signiﬁcantly associated with 2 or more
measurements of RV-PV dysfunction in a regression
analysis (p < 0.0095 for each analyte).
Many metabolites clustered within previously
deﬁned pathways. Levels of arginine-NO metabolites
(Arg-Ms: arginine, ornithine, citrulline, asymmetric
dimethylarginine, and symmetric dimethylarginine)
were related to indexes of RV-PV dysfunction
(Figure 1, Table 2). The ratio of arginine to ornithine
þ citrulline, which reﬂects global arginine bioavail-
ability and has emerged as a potential PH biomarker
in select PH populations with sickle cell disease (13)
and heart failure (1), was inversely related to PAP,
PVR, and DPQ (all p < 0.005) (Table 2). A cluster of
purine degradation products (i.e., purine-Ms: allan-
toin, xanthosine, inosine, xanthine, uric acid) was
also closely related to RV-PV dysfunction. Several
of these purine-Ms are associated with oxidative
stress, although only urate has been associated
with PH (14).
The amino acid tryptophan can be metabolized
via 2 enzymatic pathways: tryptophan hydroxylase
(TH), which yields serotonin (5-hydroxytryptophan)
and the main metabolite of serotonin (5-
hydroxyindoleacetic acid), or via IDO, which generates
kynurenine, anthranilate, kynurenate, andquinolinate.
We identiﬁed striking associations between RV-PV
dysfunction and IDO-TMs (Figure 1, Table 2) that have
FIGURE 1 Metabolic Heat Map
METABOLITE RAP mPAP PCWP PVR PVRx ΔPQ RAP mPAP PCWP PVR PVRx ΔPQ
alanine
asparagine
aspartate
glutamate
glutamine
glutamine/glutamate ratio
glycine
histidine
isoleucine
leucine
lysine
methionine
phenylalanine
proline
cistranshydroxyproline
serine
taurine
threonine
tryptophan
tyrosine
valine
arginine*
arg/(orn + citr) ratio*
adma
citrulline
nmma
ornithine
sdma
5-hiaa
hydroxytryptophan
serotonin
anthranilata*
kynurenate
kynurenine*
quinolinate*
indoxylsulfate
indole3propionate
indoleacetate
aminodipate
cystathionine*
histamine
methylhistamine
hippurate
hydroxyphenylacetate
creatine
phosphocreatine
creatinine
alphaglycerophosphocholine
betaine
choline
dimethylglycine
dhap
lactate
phosphoglycerate
pyruvate
A
BETA COEFFICIENT P VALUE
<-0.5 -0.3-0.15 -0.15-0.15 0.15-0.3 0.3-0.4 >0.4 <0.0001 <0.001 <0.01 <0.05 <0.2 >0.5
AMINO ACIDS
ARGININE METABOLITES
TRYPTOPHAN METABOLITES (TH)
TRYPTOPHAN METABOLITES (IDO)
TRYPTOPHAN METABOLITES
OTHER AMINO ACID DERIVATIVES
METHYL TRANSFER METABOLITES
GLYCOLYSIS INTERMEDIATES
b-Coefﬁcients and p values generated from regression analyses depict the relationship of each metabolite (log transformed) with hemodynamic measurements.
*p < 0.0095 for associations with 2 or more measurements of RV-PV dysfunction (see Methods). 5-hiaa ¼ 5-hydroxy-indoleacetic acid; ADMA ¼ asymmetric dimethy-
larginine; adp ¼ adenosine diphosphate; amp ¼ adenosine monophosphate; arg/(orn þ citr) ¼ ratio of arginine to sum of ornithine þ citrulline; cAMP ¼ cyclic adenosine
monophosphate; DPQ ¼ change in pressure relative to change in cardiac output during exercise; dhap ¼ dihydroxyacetone phosphate; gmp ¼ guanosine monophosphate;
IDO ¼ indoleamine 2,3-dioxygenase; imp ¼ inosine monophosphate; mPAP ¼ mean pulmonary arterial pressure; PAWP ¼ pulmonary arterial wedge pressure;
PCWP ¼ pulmonary capillary wedge pressure; PVR ¼ pulmonary vascular resistance; PVRx ¼ pulmonary vascular resistance during exercise; RAP ¼ right atrial pressure;
SDMA ¼ symmetric dimethylarginine; TCA ¼ tricarboxylic acid; TH ¼ tryptophan hydroxylase; ump ¼ uridine monophosphate; vma ¼ vanillylmandelic acid.
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FIGURE 1 Continued
METABOLITE RAP mPAP PCWP PVR PVRx ΔPQ RAP mPAP PCWP PVR PVRx ΔPQB
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179not previously been associated with PH. By contrast,
tryptophan metabolites downstream from TH were
not related to hemodynamic indexes of RV-PV
dysfunction (Figure 1). Additionally, plasma levels oftricarboxylic acid (TCA) cycle metabolites (TCA-Ms)
were closely associated with hemodynamic indexes of
RV-PV dysfunction. Although TCA intermediates
generally function intracellularly, we have previously
TABLE 2 Metabolite Levels and Hemodynamic Indexes of RV-PV Function
Metabolite RAP (Rest) mPAP (Rest) PAWP (Rest) PVR (Rest) PVR (Exercise) DPQ (Exercise)
Arg/NO metabolism
Arginine 0.29 (0.014) 0.44 (<0.001) 0.31 (0.007) 0.31 (0.008) 0.23 (0.058) 0.30 (0.013)
Citrulline 0.12 (0.337) 0.08 (0.515) 0.01 (0.940) 0.21 (0.081) 0.22 (0.069) 0.32 (0.007)
Ornithine 0.014 (0.907) 0.05 (0.682) 0.03 (0.780) 0.02 (0.880) 0.05 (0.703) 0.29 (0.013)
ADMA 0.13 (0.297) 0.12 (0.301) 0.04 (0.757) 0.16 (0.195) 0.14 (0.233) 0.30 (0.011)
SDMA 0.14 (0.234) 0.27 (0.025) 0.11 (0.373) 0.28 (0.017) 0.36 (0.002) 0.37 (.001)
Arg/(OrnþCitr) 0.21 (0.074) 0.44 (<0.001) 0.29 (0.014) 0.36 (0.002) 0.31 (0.009) 0.53 (<0.001)
Arg/NO score* 0.32 (0.007) 0.44 (0.001) 0.31 (0.019) 0.39 (0.001) 0.32 (0.006) 0.53 (<0.001)
IDO metabolites
Kynurenine 0.50 (<0.001) 0.46 (<0.001) 0.35 (0.002) 0.30 (0.012) 0.38 (0.001) 0.48 (<0.001)
Anthranilate 0.16 (0.187) 0.39 (0.001) 0.12 (0.302) 0.43 (<0.001) 0.43 (<0.001) 0.49 (<0.001)
Kynurenate 0.17 (0.168) 0.26 (0.032) 0.13 (0.262) 0.29 (0.014) 0.28 (0.02) 0.34 (0.004)
Quinolinate 0.44 (<0.001) 0.43 (<0.001) 0.26 (0.028) 0.32 (0.007) 0.39 (0.001) 0.53 (<0.001)
IDO-TM score* 0.40 (<0.001) 0.46 (<0.001) 0.29 (0.011) 0.41 (<0.001) 0.45 (<0.001) 0.55 (<0.001)
Purine metabolites
Inosine 0.31 (0.008) 0.28 (0.020) 0.26 (0.027) 0.14 (0.250) 0.16 (0.188) 0.34 (0.004)
Xanthosine 0.28 (0.021) 0.39 (0.001) 0.23 (0.052) 0.27 (0.329) 0.29 (0.051) 0.47 (<0.001)
Xanthine 0.36 (0.002) 0.34 (0.004) 0.24 (0.040) 0.24 (0.044) 0.25 (0.033) 0.40 (0.001)
Uric acid 0.38 (0.001) 0.45 (<0.001) 0.35 (0.003) 0.39 (0.001) 0.33 (0.005) 0.23 (0.054)
Allantoin 0.11 (0.363) 0.25 (0.038) 0.17 (0.165) 0.31 (0.009) 0.26 (0.029) 0.24 (0.043)
Purine score* 0.47 (<0.001) 0.46 (<0.001) 0.53 (<0.001) 0.39 (0.001) 0.36 (0.002) 0.45 (<0.001)
TCA cycle
Malate 0.27 (0.022) 0.35 (0.002) 0.20 (0.092) 0.39 (0.001) 0.30 (0.011) 0.33 (0.005)
Succinate 0.13 (0.269) 0.39 (0.001) 0.15 (0.202) 0.52 (<0.001) 0.33 (0.005) 0.24 (0.041)
Aconitate 0.15 (0.217) 0.177 (0.162) 0.16 (0.177) 0.34 (0.004) 0.30 (0.013) 0.31 (0.010)
Isocitrate 0.12 (0.335) 0.23 (0.051) 0.16 (0.196) 0.28 (0.017) 0.21 (0.081) 0.16 (0.175)
TCA score* 0.32 (0.007) 0.4 (0.001) 0.22 (0.09) 0.42 (<0.0001) 0.32 (0.006) 0.28 (0.02)
Known biomarker
NT-proBNP 0.14 (0.261) 0.40 (0.001) 0.40 (0.001) 0.30 (0.013) 0.33 (0.007) 0.38 (0.001)
Values are b-coefﬁcients (p value) and are presented to describe associations between log-transformed metabolite levels and hemodynamic measurements. *Multimarker
scores described in Methods.
ADMA ¼ asymmetric dimethylarginine; Arg/NO ¼ arginine/nitric oxide; IDO-TM ¼ indoleamine 2,3-dioxygenase tryptophan metabolite; OrnþCitr ¼ ornithine plus citrulline;
RV-PV ¼ right ventricular-pulmonary vascular; SDMA ¼ symmetric dimethylarginine; TCA ¼ tricarboxylic acid; other abbreviations as in Table 1.
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180documented that these metabolites are detectable in
plasma (15).
We next assessed interpathway and intrapathway
correlations. Relationships across annotated path-
ways are displayed in Online Table 1. Moderate cor-
relations within groups of related metabolites were
observed for IDO-TMs, TCA-Ms, purine-Ms, and Arg-
Ms, whereas TH-TMs were not strongly interrelated.
Although many of the metabolites highlighted by the
LC-MS based platform fell into previously described
pathways, other metabolites had less obvious meta-
bolic connections (Figure 1). We identiﬁed associa-
tions between indexes of RV-PV dysfunction and the
catecholamine vanillylmandelic acid, as well as ami-
noisobutyric acid and cyclic adenosine mono-
phosphate, 2 additional metabolites potentially related
to sympathetic nervous system activation (16,17).
Plasma levels of the homocysteine metabolite cys-
tathionine, as well as glyceraldehyde and glucoronate,
were also related to indexes of RV-PV dysfunction.MULTIMARKER SCORES. To assess how clusters of
metabolites from a given metabolic pathway relate to
hemodynamic measurements, composite scores were
generated by summing z-scores of individual metab-
olites weighted by b-coefﬁcients within clusters (18)
(Table 2). Composite scores from each group,
adjusted for age and sex, were closely related to PAP
and PVR at rest (Table 2). By contrast, none of the
metabolite scores were signiﬁcantly associated with
systemic MAP (data not shown). Although purine-Ms
and Arg-Ms demonstrated similar b-coefﬁcients for
PAP and PAWP, IDO-TMs and TCA-Ms demonstrated
b-coefﬁcients <0.3 with PAWP and $0.4 for PAP,
which suggests relative speciﬁcity for pre-capillary
PAP as opposed to PAP driven by left-sided ﬁlling
pressure. Moreover, IDO scores remained associated
with PAP, PVR, and DPQ (p < 0.05) after adjustment
for each of the other pathway scores. Individuals in
the top quartile of the IDO-TM score had a 2.9-fold
greater DPQ (Figure 2) and a 2.2-fold greater PVR at
FIGURE 2 Metabolite-DPQ Relationship
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The highest quartile of indoleamine 2,3-dioxygenase (IDO) tryptophan metabolite (TM)
score exhibited a much greater DPQ during exercise than the lower quartiles. DPQ
data ¼ median  interquartile range of change in mean pulmonary arterial pressure
relative to change in cardiac output.
J A C C V O L . 6 7 , N O . 2 , 2 0 1 6 Lewis et al.
J A N U A R Y 1 9 , 2 0 1 6 : 1 7 4 – 8 9 Metabolic Signatures of Pulmonary Hypertension
181rest and with exercise (p for trend < 0.001 for all).
IDO-TMs remained signiﬁcantly related to indexes
of RV-PV dysfunction after further adjustment for
NT-proBNP, a marker of myocardial wall stress and
PH (19); cystatin C, indicative of renal function; and
IL-6, an inﬂammatory cytokine previously associated
with PH (Table 3). After stepwise adjustment for the
combination of age, sex, NT-proBNP, cystatin C, and
IL-6, IDO-TM scores remained signiﬁcantly associated
with RAP, mPAP, PVR, exercise PVR, and DPQ
(p # 0.01 for all) (Table 3). Of the 4 IDO-TMs, only
kynurenate was signiﬁcantly associated with serum
creatinine (b ¼ 0.41; p ¼ 0.003). Furthermore, IDO-TM
scores were not signiﬁcantly associated with BMI,
diabetes, hypertension, smoking status, or exposure
to beta-blockers, angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers, calcium
channel blockers, diuretic agents, statins, aspirin, or
warfarin (p > 0.1 for all) (Online Table 2).
The novel ﬁnding in humans that IDO-dependent
metabolites are closely related to indexes of RV-PV
dysfunction led us to further examine their relation-
ship with other indicators of RV-PV dysfunction
beyond hemodynamic variables. IDO-TM composite
scores were inversely associated with right ventricu-
lar ejection fraction (RVEF) (b ¼ 0.38, p ¼ 0.007), and
the association with RVEF remained signiﬁcant
after adjustment for age, sex, and NT-proBNP levels
(p ¼ 0.015). Furthermore, because exercise intoler-
ance is a cardinal manifestation of RV-PV dysfunc-
tion, and reduced peak VO2 is associated with poor
prognosis in various forms of PH (20–22), we exam-
ined whether IDO-TMs also predicted impaired exer-
cise capacity. We found that higher levels of IDO-TMs
were associated with reduced percent-predicted peak
VO2, even after adjusting for NT-proBNP (b¼ 0.36; p¼
0.009). IDO-TMs thus provide markers of RV-PV
dysfunction that signal both hemodynamic impair-
ment and reduced functional capacity.
LOCALIZATION OF METABOLIC CHANGES IN HUMAN
STUDIES. To examine whether there was net uptake
or release of IDO-TMs across the pulmonary circula-
tion, we examined relative concentrations of the
4 IDO-TMs in radial arterial and proximal pulmonary
arterial samples. In subjects with normal resting PVR,
there were no signiﬁcant differences in pulmonary
and radial arterial levels of IDO-TMs (Figure 3); how-
ever, subjects with elevated PVR (>2 Wood units)
demonstrated signiﬁcantly higher radial arterial
levels of kynurenine, anthranilate, and quinolinate
than pulmonary arterial levels (p < 0.05 for all),
which indicates release of these metabolites into the
pulmonary circulation. The observed gradient inIDO-TMs across the pulmonary circulation in in-
dividuals with elevated PVR suggests a pulmonary
origin of the observed increases in circulating
IDO-TMs in patients with PV dysfunction.
LOCALIZATION OF METABOLIC CHANGES IN AN
ANIMAL MODEL. To add information regarding tissue
speciﬁcity, IDO and IDO-TMs were examined in lung
tissue from an experimental animal model of
hypoxia-induced PH (Figure 4). RV hypertrophy was
conﬁrmed by an elevated Fulton ratio of 0.35  0.02
in the hypoxia group versus 0.22  0.02 in controls
(p < 0.001). Lung messenger RNA expression of IDO
was 2.5-fold higher in mice with PH than in controls
(p < 0.001) (Figure 4A); the IDO substrate-product
ratio was elevated in lung tissue (p < 0.001)
(Figure 4B); plasma levels of IDO-TMs were elevated
in experimental PH (mean z-score: 0.42 vs. 0.50,
p ¼ 0.004) (Figure 4C), and their degree of elevation
was closely correlated to Fulton ratios (r ¼ 0.48 to
0.72; all p < 0.05).
ADDITIONAL VALIDATION STUDIES. We assessed
the performance of our metabolite biomarkers in a
second set of CPET subjects who served as a valida-
tion cohort. Multimarker combinations of metabolites
associated with RV-PV dysfunction, identical to those
identiﬁed in the derivation cohort (Table 2), demon-
strated signiﬁcant associations with indexes of RV-PV
dysfunction in the validation cohort, with the
TABLE 3 IDO-TM and Hemodynamic Measurements in Adjusted Models
Metabolite RAP (Rest) mPAP (Rest) PAWP (Rest) PVR (Rest) PVR (Exercise) DPQ (Exercise)
Models adjusted for age and sex
Kynurenine 0.50 (<0.001) 0.44 (<0.001) 0.34 (0.004) 0.28 (0.019) 0.38 (0.002) 0.49 (<0.001)
Anthranilate 0.19 (0.092) 0.34 (0.002) 0.09 (0.414) 0.37 (0.001) 0.36 (0.002) 0.39 (0.001)
Kynurenate 0.36 (0.002) 0.20 (0.078) 0.10 (0.387) 0.24 (0.037) 0.21 (0.069) 0.25 (0.038)
Quinolinate 0.45 (<0.001) 0.39 (0.001) 0.23 (0.045) 0.28 (0.017) 0.36 (0.002) 0.50 (<0.001)
IDO-TM score 0.46 (0.001) 0.42 (<0.001) 0.27 (0.019) 0.35 (0.002) 0.40 (<0.001) 0.50 (<0.001)
Models adjusted for age, sex, and log cystatin C
Kynurenine 0.01 (0.900) 0.01 (0.995) 0.06 (0.592) 0.12 (0.264) 0.06 (0.598) 0.07 (0.581)
Anthranilate 0.02 (0.803) 0.19 (0.093) 0.05 (0.655) 0.27 (0.009) 0.23 (0.032) 0.24 (0.037)
Kynurenate 0.33 (0.002) 0.23 (0.039) 0.17 (0.116) 0.13 (0.217) 0.20 (0.067) 0.30 (0.011)
Quinolinate 0.23 (0.018) 0.13 (0.184) 0.02 (0.830) 0.11 (0.251) 0.16 (0.12) 0.28 (0.008)
IDO-TM score 0.24 (0.013) 0.19 (0.046) 0.07 (0.479) 0.20 (0.031) 0.20 (0.036) 0.28 (0.007)
Models adjusted for age, sex, and log NT-proBNP
Kynurenine 0.12 (0.312) 0.12 (0.359) 0.02 (0.895) 0.17 (0.165) 0.14 (0.265) 0.18 (0.190)
Anthranilate 0.13 (0.260) 0.24 (0.043) 0.05 (0.663) 0.30 (0.009) 0.27 (0.022) 0.30 (0.016)
Kynurenate 0.45 (<0.001) 0.35 (0.008) 0.24 (0.070) 0.19 (0.147) 0.29 (0.027) 0.43 (0.002)
Quinolinate 0.42 (0.001) 0.38 (0.004) 0.16 (0.209) 0.23 (0.074) 0.33 (0.012) 0.50 (<0.001)
IDO-TM score 0.40 (<0.001) 0.34 (0.006) 0.16 (0.219) 0.27 (0.022) 0.32 (0.010) 0.44 (0.001)
Models adjusted for age, sex, and IL-6
Kynurenine 0.51 (<0.001) 0.37 (0.001) 0.22 (0.129) 0.20 (0.083) 0.27 (0.011) 0.36 (<0.001)
Anthranilate 0.21 (0.139) 0.28 (0.032) 0.06 (0.727) 0.31 (0.016) 0.25 (0.045) 0.27 (0.022)
Kynurenate 0.18 (0.167) 0.16 (0.178) 0.12 (0.398) 0.20 (0.093) 0.15 (0.180) 0.18 (0.10)
Quinolinate 0.49 (<0.001) 0.33 (0.005) 0.13 (0.389) 0.19 (0.104) 0.25 (0.024) 0.38 (<0.001)
IDO-TM score 0.47 (<0.001) 0.37 (0.002) 0.17 (0.279) 0.28 (0.024) 0.30 (0.011) 0.39 (<0.001)
Stepwise regression models adjusted for age, sex, IL-6, NT-proBNP, cystatin C
Kynurenine 0.50 (<0.001) 0.33 (0.004) 0.12 (0.200) 0.09 (0.510) 0.27 (0.022) 0.32 (0.003)
Anthranilate 0.03 (0.778) 0.13 (0.294) 0.03 (0.814) 0.34 (0.004) 0.32 (0.007) 0.16 (0.234)
Kynurenate 0.07 (0.633) 0.11 (0.478) 0.06 (0.637) 0.24 (0.038) 0.15 (0.180) 0.08 (0.528)
Quinolinate 0.44 (<0.001) 0.33 (0.005) 0.12 (0.326) 0.06 (0.71) 0.25 (0.027) 0.35 (0.002)
IDO-TM score 0.45 (<0.001) 0.31 (0.010) 0.26 (0.027) 0.31 (0.010) 0.34 (0.005) 0.38 (<0.001)
Values are b-coefﬁcients (p value) and are presented to describe associations between log-transformed metabolite levels and hemodynamic measurements.
IL ¼ interleukin; other abbreviations as in Tables 1 and 2.
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182majority of b-coefﬁcients >0.25 and p < 0.05
(Table 4). We subsequently stratiﬁed the validation
group according to whether or not abnormal pulmo-
nary vascular function was present (þPH; n ¼ 35), as
evidenced by mPAP $21 mm Hg with PVR >2.0 Wood
Units and DPQ >3.0 mm Hg/l/min (8–11,23,24), or
absent (PH; n ¼ 36). Receiver operating character-
istic curves generated for each IDO-TM in the vali-
dation cohort demonstrated C-statistics that ranged
from 0.66 to 0.74 (Figure 5A). IDO-TMs retained their
signiﬁcance in logistic regression models that
included variables known to be associated with PH
(age, sex, BMI, RVEF, and PAWP), with C-statistic
increments ranging from 0.02 to 0.09 (Table 5).
To further assess the performance of IDO-TMs as
potential markers of RV-PV dysfunction, we also
examined IDO-TM levels in an independent cohort of
patients with known World Health Organization
Group 1 PAH and control subjects of similar age,
sex, and BMI (Table 6). The 3 IDO-TMs withtranspulmonary release in the high-PVR group
(anthranilate, quinolinate, and kynurenine) demon-
strated signiﬁcantly higher levels in PAH, with C-
statistics of 0.79 to 0.86 (Figure 5B); kynurenate did
not differ between groups.
DISCUSSION
Metabolite proﬁling permits comprehensive, rela-
tively unbiased investigation of metabolic pathways
that potentially underlie complex phenotypes such
as RV-PV dysfunction. Using a mass spectrometry–
based metabolite proﬁling platform, we identiﬁed
a panel of metabolites for which the plasma con-
centrations were closely associated with RV-PV
dysfunction. Our platform highlighted small mole-
cules previously associated with RV-PV dysfunction,
including arginine-NO pathway intermediates, cat-
echolamines, and indicators of oxidative stress.
Furthermore, we identiﬁed circulating metabolites
FIGURE 3 Transpulmonary Metabolite Release
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For gradients of indoleamine 2,3-dioxygenase tryptophan metabolites across
the pulmonary circulation, the average  SD percent difference in metabolite
levels in the radial arterial samples, compared with the pulmonary arterial
samples, is indicated for subjects with pulmonary vascular resistance
(PVR) #2 Wood units (diamonds) and >2 Wood units (squares). *p < 0.05
for PVR #2 Wood units versus PVR >2 Wood units; †p < 0.05 for PVR
>2 Wood units versus no difference.
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183(TCA cycle intermediates and IDO-TMs) not pre-
viously associated with RV-PV dysfunction in
humans (Central Illustration), which represent novel
potential biomarkers of PH. IDO-TMs are particu-
larly attractive potential markers of RV-PV dys-
function because of their transpulmonary release in
patients with high PVR, their relationship with
RVEF and steep PQ, and their elevation in human
and experimental PAH. Taken together, our data
indicated that metabolite proﬁling may provide
biomarkers of PV disease and a window into the
metabolic pathways altered in RV-PV dysfunction.
A growing number of studies have evaluated po-
tential circulating biomarkers of PV disease (25,26);
however, studies to date have been largely limited to
1 or a few analytes that are compared to single resting
noninvasive estimates or measurements of right-
sided heart hemodynamics (1,14,27). A strength of
our investigation was the application of a well-
established targeted LC-MS metabolite proﬁling
platform to measure more than 100 metabolites in
carefully phenotyped derivation and validation co-
horts. Our analysis beneﬁted from blood sampling
performed in parallel with “gold standard” invasive
hemodynamic measurements at rest. We also char-
acterized multipoint pressure-ﬂow (PQ) relationships
during exercise to further reﬁne patient phenotypes
related to RV-PV function (Online Figure 1). Our
group and others have recently reported that DPQ
responses to exercise predict functional capacity and
outcomes (8,23,28,29). By linking metabolic signa-
tures to PQ responses indicative of PV reserve ca-
pacity, we may gain insight into early markers of
RV-PV dysfunction. Ultimately, biomarkers of RV-PV
dysfunction will provide the greatest utility if they
can differentiate early forms of PH before overt
disease ensues.
We found that the ratio of arginine to ornithine
þ citrulline (Arg/[OrnþCit]), which reﬂects global
arginine bioavailability, was strongly inversely
related to PAP, PVR during rest and exercise, and PQ
(Figure 1, Table 2). These ﬁndings extend previous
work demonstrating that Arg/(OrnþCit) ratio is a
marker of PH severity in select PH-populations with
sickle cell disease (13) and LV systolic dysfunction
(1). Our study documented a novel association of
these metabolites with pulmonary hemodynamic
measurements in an unselected population with
exertional dyspnea. The particularly strong rela-
tionship between Arg/(OrnþCit) levels and DPQ
suggested that this ratio may signal impaired NO-
mediated vasodilation.
In contrast to arginine pathway metabolites, the
association of IDO-TMs with PH in humans has notbeen established. The consistent, strong correlations
between the 4 IDO-TMs and indexes of RV-PV
dysfunction, coupled with their transpulmonary
release and association with RVEF, suggest that these
markers have speciﬁcity for the pulmonary circula-
tion. IDO has a known immunomodulatory role upon
induction by proinﬂammatory stimuli, including
interferon-g, and is expressed in ﬁbroblasts, macro-
phages, and vascular endothelium (30). The IDO-
product kynurenine was identiﬁed as a potential
endothelium-derived vasodilator in a murine sepsis
model (31). In vitro studies by the same group
demonstrated that kynurenine triggered dilation of
previously constricted porcine arteries. Recently, IDO
expression was localized to pulmonary endothelium
in mouse lung, and mice lacking the IDO gene
demonstrated exaggerated hypoxic pulmonary vaso-
constriction (32). Enhanced endothelial IDO amelio-
rated PH in preclinical models, modulating
PH-derived pulmonary artery smooth muscle cells
toward a proapoptotic and less proliferative/synthetic
state. However, to the best of our knowledge, there
have been no studies linking this pathway to human
disease.
IDO-TMs may be released as vasodilators in
response to PH just as natriuretic peptides are
secreted in the setting of myocardial wall stretch. As
FIGURE 4 Animal Model Studies
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Normoxia Control Hypoxia Induced PH Normoxia Control Hypoxia Induced PH
0.20
0.15
0.10
0.05
0.00
4
3
2
1
0
Tryptophan Kynerenine Kynurenate Anthranilate Quinolinate
No
rm
al
iz
ed
 ID
O1
 m
RN
A
K/
T 
Ra
tio
Fo
ld
 Δ
 v
s.
 N
or
m
ox
ia
 C
on
tr
ol
Lung IDO1 mRNA Lung K/T Ratio
*
***
*
*
*
A B
C
(A) Indoleamine 2,3-dioxygenase (IDO1) messenger ribonucleic acid (mRNA) was up-regulated in the lungs of mice with hypoxia-induced
pulmonary hypertension (PH) (n ¼ 10) compared with control mice (n ¼ 10). *p ¼ 0.01. (B) IDO activity, determined by the ratio of IDO
substrate and product (kynurenine/tryptophan [K/T]), was higher in lungs of mice with hypoxia-induced PH (n ¼ 12) than in control mice
(n ¼ 10). ***p ¼ 0.002. (C) A consistent pattern of elevation in metabolites downstream of IDO was seen in the plasma of mice with
hypoxia-induced PH (n ¼ 12) versus control mice (n ¼ 10). *p < 0.05.
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184a heme-containing enzyme, IDO may be inhibited
by NO (33), and it is plausible that production of
IDO-TMs represents a compensatory pathway acti-
vated in states of NO deﬁciency, such as RV-PV
dysfunction. Our ﬁnding that IDO-TMs were in-
versely correlated with plasma markers of Arg-NO
bioavailability (Online Table 1) supported thisTABLE 4 Validation Cohort: Metabolite Levels and RV-PV Function
Pathway RAP (Rest) mPAP (Rest) PAW
Arg/NO metabolites 0.34 (0.004) 0.36 (0.003) 0.26
IDO metabolites 0.28 (0.018) 0.43 (<0.001) 0.23
Purine metabolites 0.14 (0.25) 0.31 (0.013) 0.07
TCA metabolites 0.26 (0.027) 0.36 (0.003) 0.17
Values are b-coefﬁcients (p values) for regression analyses in the validation cohort rel
metabolites with b-coefﬁcients that achieved statistical signiﬁcance with p < 0.0125.
Abbreviations as in Tables 1 and 2.hypothesis, although further investigation of the
relationship between NO-deﬁcient states and
heightened IDO activity is needed. In contrast to our
ﬁndings related to IDO-TMs and RV-PV dysfunction,
we observed no signiﬁcant relationship between
levels of TH-TMs and RV-PV dysfunction. Serotonin
(5-hydroxytryptamine) and the serotonin metaboliteP (Rest) PVR (Rest) PVR (Exercise) DPQ (Exercise)
(0.026) 0.35 (0.014) 0.28 (0.016) 0.22 (0.064)
(0.042) 0.30 (0.010) 0.28 (0.019) 0.36 (0.002)
(0.58) 0.21 (0.07) 0.26 (0.027) 0.20 (0.10)
(0.19) 0.27 (0.024) 0.32 (0.007) 0.28 (0.019)
ating each metabolic pathway score to hemodynamic measurements. Bold indicates
FIGURE 5 ROC Analysis
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Area under ROC Curve = 0.74 (0.62-0.86) Area under ROC Curve = 0.66 (0.53-0.79)
Area under ROC Curve = 0.70 (0.57-0.82) Area under ROC Curve = 0.73 (0.60-0.85)
Area under ROC Curve = 0.79 (0.62-0.97) Area under ROC Curve = 0.85 (0.69-1.0)
Area under ROC Curve = 0.54 (0.31-0.77)
Area under ROC Curve = 0.86 (0.68-1.0)
A
B
Receiver-operating characteristic (ROC) curves and area under the curve (with 95% conﬁdence interval) values illustrate the ability of indo-
leamine 2,3-dioxygenase tryptophan metabolite levels to distinguish (A) individuals with and without right ventricular–pulmonary vascular
dysfunction in the validation dyspnea cohort stratiﬁed by the presence or absence of pulmonary arterial hypertension and (B) individuals with
known pulmonary arterial hypertension from control subjects in an independent validation cohort.
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TABLE 5 Variables Predicting the Presence of RV-PV Dysfunction
Model 1 Model 2 Model 3
C-Statistic p Value C-Statistic p Value C-Statistic p Value
Model without metabolites 0.68 0.72 0.82
Kynurenine 0.76 0.007 0.80 0.004 0.86 0.03
Quinolinate 0.72 0.05 0.75 0.07 0.85 0.13
Anthranilate 0.71 0.11 0.74 0.10 0.87 0.01
Kynurenate 0.75 0.04 0.79 0.01 0.88 0.02
IDO score 0.74 0.01 0.79 0.006 0.87 0.01
Model 1: Consists of readily available clinical variables associated with pulmonary hypertension (age, sex, body
mass index). Model 2: Adds pulmonary artery wedge pressure to model 1 variables. Model 3: Adds measured right
ventricular ejection fraction; omits body mass index based on lack of signiﬁcant association with any of the
metabolite levels or pulmonary hypertension.
Abbreviations as in Table 2.
TABLE 6 PAH Validation Cohort Characteristics
PAH (n ¼ 11) Controls (n ¼ 19) p Value
Age, yrs 44.9  19.5 39.1  10.4 0.61
Female 82 75 0.71
BMI, kg/m2 27.6  6.6 25.6  4.4 0.36
Diabetes mellitus 0 (0) 0 (0) 1.0
Obstructive sleep apnea 1 (9) 0 (0) 0.37
Systemic hypertension 1 (9) 2 (11) 0.70
Liver disease 0 (0) 0 (0) 1.0
Atherosclerosis 1 (9) 0 (0) 0.37
Active cancer 1 (9) 0 (0) 1.0
Medications
CCB 1 (9) 0 (0) 0.37
Prostacyclin 6 (55) 0 (0) 0.003
ERA 2 (18) 0 (0) 0.13
PDE5i 3 (27) 0 (0) 0.04
RAP (rest), mm Hg 11  77 NA
mPAP (rest), mm Hg 55  16 NA
PAWP (rest), mm Hg 11  77 NA
Cardiac output, l/min 3.9  1.0 NA
PVR, WU 13.1  4.3 NA
Anthranilate, AU 5.8  2.7 3.0  0.9e5 0.002
Kynurenate, AU 5.2  2.7e4 4.9  3.0e4 0.71
Kynurenine, AU 1.8  0.7e5 1.2  0.4e5 0.008
Quinolinate, AU 4.4  0.3e5 1.8  0.4e5 0.001
Values are mean  SD, %, or n (%).
AU ¼ arbitrary unit; ERA ¼ endothelin receptor antagonist; NA ¼ not available;
PAH ¼ pulmonary arterial hypertension; PDE5i ¼ phosphodiesterase type 5
inhibitor; other abbreviations as in Table 1.
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1865-hydroxyindoleacetic acid are tryptophan metabo-
lites formed in pulmonary artery endothelial cells by
TH (Figure 4A). These metabolites may contribute to
pulmonary vasoconstriction and proliferation of pul-
monary artery smooth muscle cells, but their storage
in platelets and low abundance in plasma make them
challenging and often unreliable to measure as PH
biomarkers (2,34).
Plasma levels of TCA cycle intermediates, like IDO-
TMs, were closely associated with hemodynamic in-
dexes of RV-PV function in our study. Although the
TCA cycle is operative within intracellular compart-
ments, we have previously demonstrated that TCA
cycle intermediates are detectable in plasma (35,36).
Until recently, however, a potential role of TCA cycle
intermediates in signaling biologic activity in a
hormone-like role was unrecognized. A seminal study
by He et al. (18) demonstrated that the span 1 TCA
cycle intermediate succinate was sufﬁcient to
augment blood pressure in mice by activating a novel
G protein–coupled receptor in the kidney. This group
hypothesized that release of succinate in the setting
of tissue ischemia may serve as a compensatory,
protective mechanism to maintain systemic blood
pressure. Recently, Zhao et al. (36) utilized patho-
logical specimens from explanted or resected lungs
and found elevated TCA cycle intermediates in
lungs with severe PAH. Our study extends these
ﬁndings by showing directionally concordant ele-
vations in TCA cycle intermediates measured in
plasma in patients with less advanced PV disease.
Ours is the ﬁrst study to relate circulating levels
of succinate and other TCA cycle intermediates to
PH, which raises the possibility that succinate or
potentially other TCA-related metabolites could
modulate vascular tone in humans.
There is mounting evidence of abnormal mito-
chondrial function, both within and outside thepulmonary circulation in PH. Beyond a well-
recognized glycolytic shift that occurs in PH (37),
down-regulation of the mitochondrial deacetylase
sirtuin 3 has also been implicated in mitochondrial
dysfunction in PH (38). The extent to which circu-
lating TCA cycle or glycolytic intermediates accu-
rately reﬂect mitochondrial dysfunction in PH will be
an important area of future investigation.
We also found that metabolites that may relate to
sympathetic nervous system activation tracked with
RV-PV dysfunction (i.e., vanillylmandelic acid, cyclic
adenosine monophosphate, and aminoisobutyric
acid). These ﬁndings are consistent with previous
studies relating heightened catecholamine levels to
pulmonary vasoconstriction (17).
STUDY LIMITATIONS. We used a liquid chromatog-
raphy tandem mass spectrometry platform that
provides key “sentinels” across known metabolic
pathways but does not fully cover the entire plasma
metabolome. Our study design focused on subjects
with dyspnea on exertion in the main derivation and
validation cohorts, as opposed to a narrowly deﬁned
patient population with PH, which resulted in het-
erogeneity in pathogenesis and degree of PH in
our cohort. However, because PH purports a poor
CENTRAL ILLUSTRATION Metabolic Signatures of Pulmonary Hypertension
Lewis, G.D. et al. J Am Coll Cardiol. 2016; 67(2):174–89.
Metabolic proﬁling identiﬁed novel associations of right ventricular–pulmonary vascular (RV-PV) dysfunction involving potential new biomarkers and pathways for
future research. Arg-NO ¼ arginine nitric oxide; IDO ¼ indoleamine 2,3-dioxygenase; LV ¼ left ventricle; PAP ¼ pulmonary arterial pressure; PAP/Qex ¼ pulmonary
arterial pressure ﬂow relationship during exercise; PVR ¼ pulmonary vascular resistance; PVRrest/ex ¼ pulmonary vascular resistance during rest and exercise; RAP¼ right
atrial pressure; RV ¼ right ventricle; RV-PV ¼ right ventricular-pulmonary vascular; TCA ¼ tricarboxylic acid; Vasc SMC ¼ vascular smooth muscle cell.
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187prognosis regardless of pathogenesis, biomarkers will
be most useful in their application to patients with
suspected, as opposed to conﬁrmed, pulmonary
vascular disease. Thus, our focus on dyspneic pa-
tients is advantageous in this regard. Identiﬁcation of
patients with clear evidence of pulmonary vascular
disease in our second validation cohort demonstrated
that these biomarkers performed particularly well in
separating patients with clear evidence of PAH fromthose without RV-PV dysfunction (Figure 5). Evalua-
tion of metabolite proﬁles during exercise warrants
future study as a potential way to further improve
the speciﬁcity of metabolite signatures for impaired
RV-PV reserve capacity.
Accounting for potential confounders is of critical
importance in a biomarker discovery study. Renal
dysfunction in particular is associated with increases in
several circulating metabolites, including tryptophan
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with exertional dyspnea, plasma levels of
tryptophan breakdown products, tricarboxylic acid
cycle intermediaries and purine metabolites corre-
late with the severity of pulmonary hypertension
and right ventricular dysfunction.
TRANSLATIONAL OUTLOOK: Additional research
is needed to characterize the pathophysiological path-
waysbywhich theseandothermetabolitescontribute to
pulmonary hypertension and dyspnea of hemodynamic
origin. Circulating biochemical signatures may ulti-
mately be useful for earlier patient diagnosis or to
identify those who might beneﬁt from an intervention.
Lewis et al. J A C C V O L . 6 7 , N O . 2 , 2 0 1 6
Metabolic Signatures of Pulmonary Hypertension J A N U A R Y 1 9 , 2 0 1 6 : 1 7 4 – 8 9
188metabolites that are known to be increased in the
setting of uremia (39). We excluded patients with
advanced kidney disease, and average creatinine levels
were normal in both our derivation and validation co-
horts (1.1 mg/dl in each). Furthermore, we adjusted for
cystatin C concentrations and found that IDO-TM, but
not other TMs such as indoxysulfate, remained
strongly predictive of pulmonary hemodynamic mea-
surements. Simultaneous peripheral venous and cen-
tral venous sampling was not available to permit
comparison of metabolite levels from the 2 sampling
sites. The small sample size of the validation cohort
limited our power to identify additional metabolites
that may have differed between PAH and control sub-
jects. Finally, in our animal model studies, we
acknowledge that the cellular source of metabolites
within the lung was not localized, and we did not
include invasive hemodynamic measurements to
document the degree of PH elicited by hypoxia. How-
ever, Fulton ratioswere similar to those in other studies
in which a >2-fold increment in PAP was obtained (33).
CONCLUSIONS
The present study demonstrated the potential value
of integrating metabolomic and clinical data in hu-
man cohorts who underwent detailed phenotyping
while identifying small-molecule reporters of RV-PV
function. This study begins to address an unmet
clinical need to develop noninvasive markers of
RV-PV function and reserve capacity. Novel markers
of RV-PV functional reserve may aid in earlierdetection of RV-PV dysfunction and help to quantify
the burden of RV-PV dysfunction in patients with
cardiopulmonary diseases.
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